WebDoctor Encyclopedia

Breast Invasive carcinoma Special types

Mucinous (colloid) carcinoma of the breast

Mucinous carcinoma is a special type of breast cancer whose cells float in pools of mucin. It mostly affects older women, is nearly always hormone-sensitive and rarely spreads to lymph nodes, and the pure form carries one of the best outlooks of any breast cancer.

Medically reviewed Last reviewed October 20, 2026

What is mucinous carcinoma of the breast?

Mucinous carcinoma of the breast is a special type of invasive breast cancer. It is also called colloid carcinoma. Its cancer cells float in pools of mucin, a jelly-like substance that the cells produce themselves. Under the microscope, the tumour looks like small islands of cells scattered in a lake of mucus.

Mucinous carcinoma accounts for only a small share of breast cancers, usually quoted as between 1% and 4% (Kuzmiak and Calhoun, 2023). It is most often diagnosed in older women, typically after the menopause. In a large American registry study of more than 11,000 women with the pure form, the median age at diagnosis was 71 (Di Saverio, Gutierrez and Avisar, 2008).

Doctors divide mucinous carcinoma into pure and mixed forms. Pure mucinous carcinoma is mostly mucin and has a very favourable outlook: it is usually slow growing, rarely spreads to the lymph nodes and is nearly always hormone receptor-positive. Mixed tumours contain areas of ordinary invasive breast cancer and behave more like that type.

Treatment follows the general principles for early hormone-sensitive breast cancer: surgery, often radiotherapy and, in most cases, hormone (endocrine) therapy. Chemotherapy is needed less often than for many other breast cancers.

1. Key facts at a glance

Feature Details
Type of cancer Special type of invasive breast carcinoma with abundant extracellular mucin
Also called Colloid carcinoma; mucoid or gelatinous carcinoma
How common About 1-4% of breast cancers
Typical age Usually over 60; median about 71 in a large registry
Hormone receptors Almost always oestrogen receptor-positive
HER2 Usually negative
Lymph node spread Uncommon in the pure form
Main treatment Surgery, radiotherapy and endocrine therapy
Outlook Excellent for pure mucinous carcinoma

2. Types of mucinous carcinoma

Pure and mixed

Type Mucin content Behaviour
Pure mucinous carcinoma At least 90% of the tumour Very favourable
Mixed mucinous carcinoma Between 10% and 90%, with areas of ordinary invasive carcinoma Closer to ordinary breast cancer

In a Tunisian series of 48 patients, pure and mixed tumours were found to behave as two distinct subtypes with different outcomes (El Amine El Hadj et al., 2016).

Cellular subtypes of pure mucinous carcinoma

Subtype Description
Type A (hypocellular) Few cells in large pools of mucin
Type B (hypercellular) More cells; often shows neuroendocrine features
Type AB Features of both

Conditions that look similar

Mucin production is not unique to mucinous carcinoma, so pathologists take care to distinguish it from other mucin-containing lesions (Rakha, Wazwaz and Fox, 2026).

Condition Notes
Mucocele-like lesion Benign mucin-filled cysts; may contain atypical cells
Mucinous cystadenocarcinoma A rare different cancer, often hormone receptor-negative
Solid papillary carcinoma May produce mucin
Invasive micropapillary carcinoma with mucin More aggressive
Metastasis from another organ Mucinous cancers of the bowel, ovary or appendix can spread to the breast

How it compares with the most common breast cancer

Feature Pure mucinous carcinoma Invasive carcinoma of no special type
Typical age Older, often over 70 Wide range, often 50-70
Grade Usually low or intermediate Any grade
Oestrogen receptor-positive Nearly all About 3 in 4
Lymph node spread at diagnosis Uncommon More common
Appearance on mammogram Smooth, well-defined mass Often spiculated (spiky)
Long-term outlook Very good Good, but lower on average

In the registry study, around 86% of women had disease confined to the breast at surgery, about 12% had lymph node involvement and only 2% had distant spread (Di Saverio, Gutierrez and Avisar, 2008).

Mucinous carcinoma in men

Breast cancer in men is rare, and mucinous carcinoma is an uncommon type within it. When it does occur, it is treated in the same way, usually with mastectomy, sentinel node biopsy and tamoxifen.

3. Causes and risk factors

There is no single known cause. Risk factors are broadly the same as for hormone receptor-positive breast cancer.

Risk factor Notes
Older age The main factor; most cases occur after the menopause
Female sex Men are rarely affected
Hormonal factors Early periods, late menopause, hormone replacement therapy
Family history Increases breast cancer risk in general
Alcohol and excess weight after menopause Increase breast cancer risk

4. How does it look

On mammography

Feature Description
Shape Round, oval or lobulated mass
Edge Often well defined (circumscribed)
Density Equal to or higher than surrounding tissue
Calcium Uncommon
Risk of confusion Can look like a benign lump such as a fibroadenoma or cyst

On ultrasound and MRI

Test Typical appearance
Ultrasound A well-defined mass that may look similar in brightness to fat; sometimes mistaken for a cyst
MRI Very bright on T2-weighted images because of the mucin; gradual enhancement

Because it can resemble a benign lesion, a biopsy is important whenever a new mass appears in an older woman (Kuzmiak and Calhoun, 2023).

Under the microscope

Feature Description
Mucin Large pools of pale blue extracellular mucin separated by fine fibrous bands
Cells Clusters, cords or small sheets floating in mucin
Nuclear grade Usually low or intermediate
Receptors Oestrogen and progesterone receptor-positive in the vast majority
HER2 Usually negative (luminal A-like)

To the touch

When a lump can be felt, it is often soft or rubbery and may move easily, which can be falsely reassuring.

5. Symptoms

Common findings

  • No symptoms, with the cancer found on screening mammography
  • A painless lump in the breast
  • A lump that may feel soft or squashy rather than hard

Less common symptoms

Symptom What it may mean
Change in breast shape or size Large tumour
Skin dimpling or puckering Tumour pulling on the skin
Nipple changes Tumour near the nipple
Lump in the armpit Possible lymph node spread, which is uncommon

When to seek medical advice

See a doctor about any new breast lump, even if it feels soft or moves, and about changes in the skin or nipple. Keep attending breast screening when invited.

6. Diagnosis

Test Purpose
Clinical breast examination Assesses the lump and lymph nodes
Mammography Shows the mass and any other lesions
Ultrasound Characterises the mass and checks the armpit
Core needle biopsy Confirms mucinous carcinoma and tests receptors
Oestrogen, progesterone and HER2 testing Guides treatment
MRI In selected cases, for extent or other tumours
Staging scans Usually not needed for small node-negative tumours

A core biopsy may contain mostly mucin, so the final classification as pure or mixed is often confirmed after surgery.

Staging

Mucinous carcinoma is staged with the standard TNM breast cancer system, including tumour size, lymph nodes, spread and the tumour’s receptor status and grade.

The mucin makes tumours larger than their cancer-cell content would suggest, which has led some experts to question how well tumour size predicts outcome in this type (Di Saverio, Gutierrez and Avisar, 2008).

7. Treatment

Surgery

Option Notes
Breast-conserving surgery (wide local excision) Suitable for most tumours
Mastectomy For larger tumours, several tumours or by choice
Sentinel lymph node biopsy Checks the first draining nodes in the armpit
Axillary clearance Only if several nodes are involved

Radiotherapy

Situation Role
After breast-conserving surgery Usually advised to reduce the risk of the cancer returning in the breast
Older women with small, low-risk tumours Radiotherapy may sometimes be omitted if endocrine therapy is taken
After mastectomy Only for higher-risk features

In the registry study, adding radiotherapy after surgery did not significantly change overall survival, although it can lower the chance of a local recurrence (Di Saverio, Gutierrez and Avisar, 2008).

Endocrine therapy

Drug Notes
Aromatase inhibitors (anastrozole, letrozole, exemestane) Usual choice after the menopause
Tamoxifen For premenopausal women or if aromatase inhibitors are unsuitable
Duration Typically 5 years, sometimes longer

Chemotherapy and other treatments

Situation Approach
Pure, node-negative, low-grade tumours Chemotherapy is rarely needed
Mixed tumours or node-positive disease May be considered, guided by risk
Genomic tests (for example Oncotype DX) Help decide whether chemotherapy would add benefit
HER2-positive tumours (rare) Anti-HER2 therapy such as trastuzumab
Metastatic disease Endocrine therapy with CDK4/6 inhibitors, among other options

Side effects

Treatment Possible side effects
Surgery Pain, bruising, change in breast shape, arm swelling after node surgery
Radiotherapy Skin redness, tiredness, breast firmness
Aromatase inhibitors Joint aches, hot flushes, bone thinning
Tamoxifen Hot flushes, small risk of blood clots and womb lining changes

What treatment involves day to day

Stage What to expect
Surgery Often a day case or one night in hospital
Recovery 2-4 weeks for most daily activities
Radiotherapy Usually 1-3 weeks of weekday sessions
Endocrine therapy A daily tablet for several years

8. Outlook (prognosis)

Pure mucinous carcinoma has one of the best outlooks of any breast cancer type.

Measure Pure mucinous carcinoma Invasive ductal carcinoma (same registry)
Breast cancer-specific survival at 5 years About 94% About 82%
At 10 years About 89% About 72%
At 20 years About 81% About 62%

These figures come from more than 11,000 women recorded between 1973 and 2002 (Di Saverio, Gutierrez and Avisar, 2008). Outcomes today are likely to be better still with modern treatment.

Factor Effect on outlook
Lymph node involvement The strongest predictor of worse outcome
Mixed rather than pure type Poorer outlook
Larger size and higher grade Poorer outlook
Progesterone receptor-positive Better outlook
Older age Shorter overall survival, partly due to other illnesses

Late recurrences can occur, so long-term follow-up is worthwhile.

9. Follow-up

Follow-up Purpose
Yearly mammograms Check both breasts
Clinic or nurse review Discuss symptoms and side effects
Bone density scans If taking aromatase inhibitors
Adherence support Help with continuing endocrine therapy
Long-term awareness Recurrence can occur many years later

10. Living with mucinous carcinoma

  • Take endocrine therapy daily and tell your team about side effects; alternatives are available
  • Keep active; exercise helps joint aches, mood and bone health
  • Look after your bones with calcium, vitamin D and weight-bearing exercise
  • Check your breasts and scar and report new lumps or changes
  • Limit alcohol and keep a healthy weight, which benefits overall health
  • Keep attending screening or follow-up mammograms, even many years after treatment
  • Seek support from breast cancer charities and local groups

11. Frequently asked questions

Question Answer
Is mucinous carcinoma less serious than other breast cancers? Pure mucinous carcinoma usually has an excellent outlook
Why did the lump feel soft? The mucin gives the tumour a soft or rubbery texture
Will I need chemotherapy? Usually not for pure, node-negative tumours
Do I still need hormone tablets? Yes, in most cases, as these tumours are hormone-sensitive
Can it come back? Yes, though less often than many other types; recurrence can be late
Is it inherited? Usually not, but family history is assessed as for any breast cancer
What is the difference between pure and mixed? Pure tumours are mostly mucin; mixed tumours contain ordinary breast cancer too
Can men get it? Yes, rarely; treatment is similar
Does the mucin itself cause harm? No; it makes the tumour look larger but is not itself dangerous

12. Questions to ask your care team

  • Is my tumour pure or mixed mucinous carcinoma?
  • What are the receptor results and grade?
  • Were any lymph nodes involved?
  • Do I need radiotherapy, and could I safely avoid it?
  • Would a genomic test help decide about chemotherapy?
  • Which endocrine therapy do you recommend, and for how long?
  • How will my bone health be monitored during treatment?

Resources

  1. Di Saverio, S., Gutierrez, J. and Avisar, E. (2008) ‘A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma’, Breast Cancer Research and Treatment, 111(3), pp. 541-547.
  2. El Amine El Hadj, O. et al. (2016) ‘Mucinous breast carcinoma a rare entity to be known: clinico-pathological study of 48 cases’, La Tunisie Medicale, 94(8-9), pp. 525-530.
  3. Kuzmiak, C.M. and Calhoun, B.C. (2023) ‘Pure mucinous carcinoma of the breast: radiologic-pathologic correlation’, Journal of Breast Imaging, 5(2), pp. 180-187.
  4. Rakha, E.A., Wazwaz, B. and Fox, S.B. (2026) ‘Mucinous carcinoma of the breast: morphological spectrum, diagnostic pitfalls and classification challenges’, Journal of Clinical Pathology, 79(7), pp. 433-444.
  5. National Cancer Institute (2026) Breast Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/breast/hp/breast-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.